T1	intervention 23 29	RGB-02
T2	condition 69 101	chemotherapy-induced neutropenia
T3	eligibility 635 685	breast cancer patients receiving cytotoxic regimen
T4	total-participants 687 710	Two hundred thirty-nine
T5	intervention-participants 778 781	121
T6	control 791 808	reference product
T7	control-participants 814 817	118
T10	outcome-Measure 1173 1205	incidence of febrile neutropenia
T11	outcome-Measure 1207 1227	time to ANC recovery
T12	outcome-Measure 1229 1248	depth of ANC nadir,
T13	outcome-Measure 1253 1268	safety outcomes
T15	outcome 1681 1696	Safety profiles
T16	iv-cont-mean 1325 1328	1.7
T17	cv-cont-mean 1342 1350	1.6 days
T8	outcome 1274 1320	mean duration of severe neutropenia in Cycle 1
T9	outcome-Measure 1002 1063	duration of severe neutropenia (ANC < 0.5 × 109/L) in Cycle 1
